1 Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an

open-label, randomised, controlled, adaptive platform trial (PLATCOV)

3

•				
4	Podjar	odjanee Jittamala MD ^{1,2+} , Simon Boyd MBBS ^{1,3+} , William HK Schilling MBBS ^{1,3*} , James A		
5	Watson DPhil ^{1,4} , Thundon Ngamprasertchai MD ⁵ , Tanaya Siripoon MD ⁵ , Viravarn Luvira MD ⁵ ,			
6	Elizabeth M Batty PhD ^{1,3} , Phrutsamon Wongnak PhD ¹ , Lisia M Esper ⁶ , Pedro J Almeida ⁶ , Cintia			
7	Cruz MD ^{1,2} , Fernando R Ascencao ⁷ , Renato S Aguiar ⁸ , Najia K Ghanchi PhD ⁹ , James J Callery MB			
8	ChB ^{1,3} , Shivani Singh MBBS ¹ , Varaporn Kruabkontho PhD ¹ , Thatsanun Ngernseng MBA ¹ , Jaruwa			
9	Tubprasert Pharm.D ¹ , Wanassanan Madmanee BSc ¹ , Kanokon Suwannasin BSc ¹ , Amornrat			
10	Promsongsil ¹ , Borimas Hanboonkunupakarn MD ^{1,5} , Kittiyod Poovorawan MD ^{1,5} , Manus			
11	Potaporn MD ¹⁰ , Attasit Srisubat MD ¹⁰ , Bootsakorn Loharjun MD ¹⁰ , Walter RJ Taylor FRCP ^{1,3} ,			
12	Farah Qamar MBBS FRCP ⁹ , Abdul Momin Kazi MBBS ⁹ , M. Asim Beg FRCP(Edin) ⁹ , Danoy			
13	Chommanam ¹¹ , Sisouphanh Vidhamaly ¹² , Kesinee Chotivanich PhD ^{1,5} , Mallika Imwong PhD ^{1,11} ,			
14	Sasithon Pukrittayakamee MBBS ^{1,5} , Arjen M Dondorp FMedSci ^{1,3} , Nicholas PJ Day FMedSci ^{1,3} ,			
15	Mauro M Teixeira MD ⁶ , Watcharapong Piyaphanee MD ⁵ , Weerapong Phumratanaprapin MD ⁵ ,			
16	Nicholas J White FRS ^{1,3**} , on behalf of the PLATCOV Collaborative Group.			
17	1.	Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol		
18		University, Bangkok, Thailand		
19	2.	Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University,		
20		Bangkok, Thailand		
21	3.	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,		
22		University of Oxford, Oxford, UK		
23	4.	Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam		
24	5.	Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol		
25		University, Bangkok, Thailand		
26	6.	Clinical Research Unit, Center for Advanced and Innovative Therapies, Universidade		
27		Federal de Minas Gerais, Belo Horizonte, Brazil		

- 28 7. Department of Biochemistry and Immunology, Universidade Federal de Minas Gerais,
- 29 Belo Horizonte, Brazil
- 30 8. Department of Genetics, Ecology and Evolution, Institute of Biological Sciences,
- 31 Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- 32 9. Aga Khan University, Karachi, Pakistan
- 33 10. Department of Medical Services, Ministry of Public Health, Bangkok, Thailand
- 34 11. Laos-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory,
- 35 Mahosot Hospital, Vientiane, Laos P.D.R.
- 36 12. Pulmonology Department, Mahosot Hospital, Vientiane, Laos P.D.R.
- 37 13. Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine,
- 38 Mahidol University, Bangkok, Thailand
- 39
- 40 +: Equal contributions
- 41 *Correspondence: William HK Schilling
- 42 Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol
- 43 University, 420/6 Rajvithi Rd, Bangkok, 10400, Thailand; email william@tropmedres.ac
- 44 **Alternate correspondence: Nicholas J White

45 Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol
46 University, 420/6 Rajvithi Rd, Bangkok, 10400, Thailand; email <u>nickw@tropmedres.ac</u>

- 47
- 48
- 49

50 Abstract

51 Background

The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine were repurposed for the treatment of early COVID-19 based on their antiviral activity *in vitro*, and observational and clinical trial evidence suggesting they prevented progression to severe disease. However, these SSRIs have not been recommended in guidelines and their antiviral activity *in vivo* has not been characterised.

57

58 Methods

59 PLATCOV is an open-label, multicentre, phase 2, randomised, controlled, adaptive 60 pharmacometric platform trial running in Thailand, Brazil, Pakistan, and Laos. We recruited low-61 risk adult outpatients aged 18-50 with early symptomatic COVID-19 (symptoms <4 days). Patients 62 were assigned using block randomisation to one of eleven treatment arms including oral 63 fluoxetine (40mg/day for 7 days), or no study drug. Uniform randomisation ratios were applied 64 across the active treatment groups while the no study drug group comprised ≥20% of patients at 65 all times.

The primary endpoint was the rate of oropharyngeal viral clearance assessed in a modified intention-to-treat population (>2 days-follow-up). The viral clearance rate was estimated under a Bayesian hierarchical linear model fitted to the log10 viral densities in standardised duplicate oropharyngeal swab eluates taken daily over one week (18 measurements per patient). This ongoing trial is registered at ClinicalTrials.gov (NCT05041907).

71

72 Findings

Between 5 April 2022 and 8 May 2023 271 patients were concurrently randomised to either fluoxetine (n=120) or no study drug (n=151). Fluoxetine was well tolerated and accelerated the rate of viral clearance relative to the no study drug arm by 15% (95% credible interval (CrI): 2% to 34%). In a pooled meta-analysis including all unblinded patients the antiviral activity of fluoxetine was substantially less than ritonavir-boosted nirmatrelvir- 85% increase in rate of viral

- clearance (95% CrI: 61 to 112%); and less than remdesivir 35% (14 to 59%), molnupiravir 37% (18
- to 60%), and casirivimab/imdevimab 29% (10 to 48%).
- 80

81 Interpretation

- 82 Fluoxetine has *in vivo* antiviral activity against SARS-CoV-2. Although the level of antiviral efficacy
- is substantially less than with other currently available antiviral drugs, fluoxetine might still be
- 84 useful in prophylaxis where less antiviral effect is required.
- 85

86 Funding

- 87 Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.
- 88
- 89

90 Evidence before this study

91 The SSRIs fluoxetine and fluvoxamine have been proposed as COVID-19 therapeutics based initially on observational, randomised trial and in vitro evidence. The observational reports 92 suggested that patients taking SSRIs had a reduced probability of developing severe COVID-19 93 and dying. We searched PubMed and EMBASE for studies in English up until the 30th November 94 2023 using the search terms "fluoxetine", "fluvoxamine" and "COVID-19" with the search 95 96 restricted to randomised controlled trials (RCTs). Eight outpatient fluvoxamine RCTs were 97 identified. There were no fluoxetine RCTs in outpatients. A meta-analysis of available RCTs is 98 compatible with a moderate reduction in hospitalisation and death in COVID-19 patients with an 99 estimated risk ratio of 0.80 (95% CI: 0.62,1.01).

100 Added value of the study

101 We showed that in early COVID-19 illness the SSRI fluoxetine has weak antiviral activity *in vivo*. 102 This activity is substantially less than other available antivirals such as ritonavir-boosted 103 nirmatrelvir and molnupiravir. The pharmacometric approach described here provides a 104 quantitative measure of *in vivo* antiviral effects with tractable sample sizes.

105 Implications of available evidence

Fluoxetine has weak *in vivo* antiviral activity in early COVID-19. This is insufficient for treatment
but, as less antiviral activity is required to prevent an infection, fluoxetine could still be beneficial
in prophylaxis.

109 Introduction

110 Repurposing of existing small molecule drugs can provide affordable and widely available 111 treatment options. At the beginning of the COVID-19 pandemic there was considerable interest 112 in drug repurposing, but there was little success in demonstrating clinical efficacy apart from the 113 use of immunomodulatory drugs for severe and hospitalised patients (e.g. dexamethasone),¹ No 114 clear benefits were demonstrated for the initial antiviral candidates. Now, four years later, there 115 are several approved efficacious antiviral drugs to treat early symptomatic COVID-19, but these 116 are expensive, and they are not widely available. Ritonavir-boosted nirmatrelvir is currently the

most effective small molecule antiviral drug but, apart from its very high cost (up to \$500 USD/course), it has other drawbacks including drug interactions, dysgeusia, and is associated with viral rebound. The only other widely available efficacious oral drug, molnupiravir, has concerns over generation of mutant viruses.^{2,3} There remains a need for effective, reliable, accessible, and affordable antiviral treatments for early COVID-19.

122

Selective serotonin reuptake inhibitors (SSRIs) are the most widely used class of antidepressants. 123 They are readily available and affordable globally. In some countries over 10% of the adult 124 125 population are taking SSRIs. Observational studies early in the pandemic suggested that patients taking fluoxetine had reduced mortality when admitted to hospital with COVID-19.^{4,5} Subsequent 126 studies supported this observation,^{6,7} and also suggested that SSRIs confer a prophylactic 127 benefit.⁸ Another SSRI, fluvoxamine, was assessed in a meta-analysis of 8 randomised clinical 128 trials.⁹⁻¹⁶ (there were no outpatient randomised controlled trials for fluoxetine; supplementary 129 130 appendix subsection S12). Treatment with fluvoxamine was compatible with a moderate 131 reduction in hospitalisation or death in COVID-19 outpatients, with an estimated risk-ratio of 0.80 132 (95% CI: 0.62 to 1.01, Figure S2).

133

The proposed mechanism of action of SSRIs is through functional inhibition of acid 134 sphingomyelinase (so-called FIASMAs). This interferes with intracellular endolyosomal viral 135 trafficking.¹⁷Although many drugs are classified as FIASMAs, and some of the earlier research 136 137 focussed on the closely related compound fluvoxamine, fluoxetine, which is on the WHO's list of Essential Medications,¹⁸ was found to have the greatest *in vitro* FIASMA activity, the best 138 139 tolerability profile, and the most favourable pharmacokinetic properties.¹⁹ In vitro anti-SARS-140 CoV-2 activity has been shown at fluoxetine concentrations approximating those during the treatment of depression (20 mg daily; 0.8 µg/ml, 2.6 µM).²⁰ Pharmacokinetic modelling 141 142 determined that an adult dose of 40 mg per day would provide at least 85% of patients with the 143 trough target plasma concentrations needed to reach the estimated target 90% maximal effective concentration (EC90) within 3 days,²¹ although the justification for the extrapolated 144 145 concentration target is not strong.

It is no longer feasible to conduct randomised trials assessing prevention of hospitalisation and 146 147 death in outpatients with symptomatic COVID-19, as was done earlier in the pandemic. Even in 148 high-risk patients, the proportion of patients with COVID-19 who progress to severe illness 149 and/or require hospitalisation is now very low (<1%).²² For drugs with weak or moderate antiviral activity (such as fluoxetine) the sample sizes needed to show a clinical benefit have therefore 150 become prohibitively large. An alternative approach for candidate antiviral drugs in early COVID-151 19 is to assess their *in vivo* pharmacodynamics i.e. their effects on the rate of viral clearance. 152 Acceleration in viral clearance correlates with clinical benefit.^{23,24} 153

154

PLATCOV is an adaptive platform trial in adults with acute early COVID-19. The PLATCOV trial methodology can evaluate antiviral activity rapidly and compare available treatments quantitatively.^{2,25-27} Here we report the results for fluoxetine and contextualise this by pooling all unblinded data from the platform and comparing fluoxetine with the other assessed antiviral interventions.

160 Methods

161 Study design

162 PLATCOV is an ongoing phase 2, open label, multicentre, randomised, controlled, adaptive 163 platform trial running currently in Thailand, Brazil, Pakistan, and Laos (ClinicalTrials.gov: 164 NCT05041907). The trial provides a standardised quantitative comparative methodology for in 165 vivo assessment of potential antiviral treatments in low-risk adults with early symptomatic 166 COVID-19. Potential antiviral treatments are entered into the platform when they become 167 available, and they are removed when the prespecified stopping rules are reached. Enrolled 168 patients were admitted to the study ward or managed as outpatients according to patient 169 preference (none of the admissions were for clinical reasons, but for ease of adherence with the 170 study procedures, or for self-isolation).

171

Standard symptomatic treatment was provided to all patients. Initially, the following drugs were
studied: ivermectin, favipiravir, remdesivir, and casirivimab/imdevimab (monoclonal antibody

174 cocktail). These groups have already reached the prespecified stopping rules for efficacy or lack 175 of efficacy and so have been stopped^{2,25-27}. Additional groups; ensitrelvir, molnupiravir, ritonavir-176 boosted nirmatrelvir, and the tixagevimab/cilgavimab monoclonal antibody cocktail, were 177 introduced later. The primary analysis reported here includes the results from patients who were 178 allocated concurrently to fluoxetine or no study drug (negative control). In addition, we present 179 a meta-analysis of all small molecule drugs and monoclonal antibodies with unblinded data to 180 provide a calibration of the effect sizes observed for fluoxetine.

181

PLATCOV is coordinated and monitored by the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, is overseen by a trial steering committee (TSC), conducted according to Good Clinical Practice principles, and approved by the local IRB/EC (see supplementary materials subsection S2). The results were reviewed regularly by a data and safety monitoring board (DSMB). The funders had no role in the design, conduct, analysis, or interpretation of the trial.

187

188 Participants

189 Previously healthy non-pregnant adults aged between 18 and 50 years were eligible for 190 enrolment in the trial if they had early symptomatic COVID-19 (i.e. symptoms for <4 days), oxygen 191 saturation \geq 96%, were unimpeded in activities of daily living, and gave fully informed written 192 consent. SARS-CoV-2 positivity was defined either as a nasal lateral flow antigen test which 193 became positive within two minutes (STANDARD® Q COVID-19 Ag Test, SD Biosensor, Suwon-si, 194 Korea) or a positive PCR test with a cycle threshold value (Ct) <25 (all viral gene targets) within 195 the previous 24 hours. Both tests ensure the majority of recruited patients have high viral loads. 196 Exclusion criteria included taking any potential antivirals or pre-existing concomitant 197 medications, chronic illness or significant comorbidity, haematological or biochemical 198 abnormalities (haemoglobin <8 g/dL, platelet count <50,000/ μ L, abnormal liver function tests, 199 and estimated glomerular filtration rate <70 mL/min per 1.73 m²), pregnancy (a urinary 200 pregnancy test was performed in females), breastfeeding, or contraindication or known 201 hypersensitivity to any of the study drugs.

202

203 Randomisation and interventions

204 Block randomisation was performed via a centralised web-app designed by MORU software 205 engineers using RShiny[®] hosted on a MORU webserver (supplementary appendix subsection S8). 206 At enrolment, after obtaining fully informed consent and entering the patient details, the app 207 provided the study drug allocation. The "no study drug" arm was allocated to a minimum 208 proportion of 20% of patients, with uniform randomisation ratios applied across the other active 209 treatment arms. The trial was open label as it was impractical to conceal the different 210 interventions. The viral densities were measured blinded to treatment allocation. Fluoxetine was 211 added to the platform on the 5th May 2022 in Thailand, and the 21st June 2022 in Brazil, Laos, and Pakistan. Fluoxetine was removed on the 8th May 2023. During this period, patients were also 212 randomised to remdesivir (until 10th June 2022), casirivimab/imdevimab (Thailand only, until 20th 213 October 2022), favipiravir (until 30th October 2022), molnupiravir (until 22nd February 2023), 214 tixagevimab/cilgavimab (until 4th July 2023), nitazoxanide (Brazil, Laos and Pakistan, from 18th 215 January 2022 ongoing), ensitrelvir (Thailand and Laos only, from 17th March 2023, ongoing), and 216 ritonavir-boosted nirmatrelvir (from 6th June 2022, ongoing as positive control). 217

218

219 Procedures

220 All study drugs were stored under the appropriate conditions. Fluoxetine (Anzac [®]: Bangkok Lab 221 Cosmetic in Thailand and Laos, Prozac[®]: Eli Lilly in Brazil and Flux, Hilton Pharma in Pakistan) was 222 given at an oral dose of 40 mg per day for a total of seven days starting at baseline. The 223 administration of all drugs was observed directly or via video. After randomisation and baseline 224 procedures (see appendix page 9) oropharyngeal swabs (two swabs taken from each tonsil) were 225 taken as follows. A flocked swab (Thermo Fisher MicroTest [Thermo Fisher, Waltham, MA, USA] 226 and later COPAN FLOQSwabs[®] [COPAN Diagnostics, Murrieta, CA, USA]), was rotated against the 227 tonsil through 360° four times and placed in Thermo Fisher M4RT (Thermo Fisher, Waltham, MA, 228 USA) viral transport medium (3 mL). The swabs were transferred at 4–8°C, aliquoted, and finally 229 frozen at -80°C within 48 hours. Separate swabs from each tonsil were taken once daily from day

0 to day 7, on day 10, and on day 14. Swabs were processed and tested separately. Vital signs
were recorded three times daily by the patient (on the first day the initial vital signs were
recorded by the study team). Symptoms and any adverse effects were recorded daily.

233 The TagCheck[®] SARS-CoV-2 Fast PCR Assay (Applied Biosystems, Thermo Fisher Scientific, 234 Waltham, MA, USA) quantitated viral loads (RNA copies per mL). This multiplexed real-time PCR method detects the SARS-CoV-2 N and S genes, and human RNase P gene in a single reaction. 235 236 RNase P was used to adjust for variation in sample human cell content (see appendix page 20). 237 Viral loads were quantified against ATCC (Manassas, VA, USA) heat-inactivated SARS-CoV-2 (VR-238 1986HK strain 2019-nCoV/USA-WA1/2020) standards. Whole genome sequencing was 239 performed to genotype strains and classify the viral variants (see supplementary appendix 240 subsection S7).

241

242 Outcomes

243 The primary outcome measure was the rate of viral clearance estimated from viral genome

244 densities in serial duplicate oropharyngeal viral swab eluates taken daily between days 0 and 7

245 (see statistical methods below and supplementary appendix S9 for the method of estimation).

246 Secondary endpoints were:

247 (i) all-cause admission to hospital for clinical deterioration (until day 28);

248 (ii) time-to-resolution of fever in patients febrile at admission;

249 (iii) time-to-resolution of symptoms.

These endpoints were assessed using survival methods because the data at the last visit were right-censored. Patients were defined as febrile at admission if at least one axillary temperature measurement within 24 hours of randomisation was \geq 37.5°C. Resolution of fever was defined as an axillary temperature \leq 37.0°C for at least 24 hours. Symptom resolution was defined as no reported symptoms. All adverse events were graded as per the Common Terminology Criteria for Adverse Events version 5.0.²⁸ Summaries were generated if the adverse event was grade 3 or worse, and was new or had increased in intensity. Serious adverse events were recorded

separately and reported to the data safety monitoring board, however there were no seriousadverse events during this portion of the trial.

259

260 Sample size and analysis framework

For each intervention, the sample size was adaptive, based on the prespecified futility and success stopping rules. A maximum sample size of 120 patients was prespecified (this does not include the no study drug arm or the positive control arm - currently ritonavir-boosted nirmatrelvir). Sample size requirements and thresholds for stopping rules were determined by simulation (see statistical analysis plan supplementary appendix subsection S9).

266

267 The primary outcome measure, the rate of viral clearance between day 0 and day 7, was 268 expressed as a slope coefficient and estimated under a Bayesian hierarchical linear model with random effect terms for the individual patient slope and intercept.^{25,29} The model was fitted to 269 270 the daily log_{10} oropharyngeal swab eluate viral densities (genomes/mL) between days 0 and 7 (18 271 measurements per patient), using weakly informative priors and treating non-detectable viral loads (CT value \geq 40) as left-censored (supplementary appendix subsection S9).²⁵ The treatment 272 effect was defined as the multiplicative change (%) in the viral clearance rate, either relative to 273 274 the no study drug arm (when determining if an intervention had an antiviral effect), or relative to the positive control arm (ritonavir-boosted nirmatrelvir).²⁹ The viral clearance rate (i.e., slope 275 276 coefficient from the model fit) can also be expressed as a clearance half-life ($t_{1/2} = \log_{10} 0.5 / \text{slope}$). 277 A 50% increase in clearance rate equals a 33% reduction in clearance half-life. All models include 278 as covariate terms on the slope coefficient the time since study commencement, the virus 279 variant, and the study site.

280

Because of the changing pattern of viral variants, and the substantial increase in the rate of viral clearance since the beginning of the pandemic, each of the studied interventions was compared only against the concurrent controls, with interim analyses planned every additional ten patients recruited into each group. However, in practice, the interim analyses were less frequent than planned as recruitment occurred quickly. At first, all interim analyses compared the new

286 intervention against the no study drug group. The protocol stipulated dropping the intervention 287 for futility when there is >90% probability that it accelerated viral clearance by less than 20% (this 288 threshold was increased from 12.5% in January 2023; statistical analysis plan version 3.0). If the 289 new intervention reaches the success threshold (i.e., >90% probability it accelerated viral 290 clearance >20% relative to no study drug), it is then compared with the positive control. This 291 secondary comparison terminates when the intervention is shown to be inferior, non-inferior, or 292 superior to the positive control group using a 10% non-inferiority margin. If the intervention is 293 superior, it then replaces the positive control group. All stopping decisions are made using data 294 from contemporaneously randomly assigned patients only.

295

All efficacy analyses were done in a modified intention-to-treat (mITT) population, comprising all patients with >2 days follow-up data. Safety data were analysed in all patients who had received > one dose of the study drug. A sensitivity analysis was performed using a non-linear model fitted to the serial viral densities, which allows for an initial increase followed by a log-linear decrease (Supplementary appendix subsection S9).

301

302 Additional post hoc analyses

303 A recent analysis of all available PLATCOV trial unblinded data (N>1200 patients) characterised 304 the substantial increase in viral clearance rates that has occurred since the beginning of the 305 platform trial 28 months ago. The average oropharyngeal viral clearance half-life in the no study drug arm has shortened from ~17 hours in late 2021 to ~9 hours in October 2023.³⁰ This analysis 306 307 also showed that restricting the primary endpoint to the clearance rate estimated over the first 308 5 days, instead of 7 days, resulted in greater power to assess treatment effects (i.e. larger z-scores 309 between effective and ineffective or no drug arms). A post-hoc analysis of the fluoxetine data 310 was therefore added in which the estimation of the viral clearance rates was made from the first 311 5 days only.

312 Meta-analysis

To calibrate the effect sizes observed for the fluoxetine arm, an individual patient data metaanalysis was conducted of all small molecule drugs and monoclonal antibodies with unblinded data from the PLATCOV trial (favipiravir, remdesivir, molnupiravir, ritonavir-boosted nirmatrelvir, casirivimab/imdevimab and ivermectin). Not all interventions were randomised concurrently, so the time since study commencement was included as a covariate on the mean slope parameter to control for temporal confounding.

319

320 Statistical analysis

321 All data analysis was done in R version 4.3.2. Posterior distributions were approximated using Hamiltonian Monte Carlo in Stan via the RStan interface.³¹ 4,000 iterations were run over four 322 independent chains with 2000 iterations for burn-in. Convergence was assessed visually from the 323 324 trace plots (Figures S4 and S5) and using the R-hat statistic (a value <1.1 was considered 325 acceptable convergence). Goodness of fit was assessed by plotting the residuals over time and 326 comparing the daily median model predictions with the observed values (Figure S5). All point 327 estimates are reported with 95% credible intervals (CrIs), defined by the 2.5% and the 97.5% 328 quantiles of the posterior distribution. Model fits were compared using approximate leave-oneout comparison as implemented in the package loo .³² 329

330 **Results**

The PLATCOV platform trial began recruitment on 30th September 2021. The fluoxetine arm was 331 added in Thailand on 5th April 2022, and in the other sites on the 21st June 2022, and was stopped 332 333 on 8th May 2023 after 120 patients had been randomised to fluoxetine. Of the 675 patients randomised during that period, 120 patients were randomised to fluoxetine, 151 to no study 334 335 drug, and the remaining 404 were randomised to other interventions (casirivimab/imdevimab, 336 tixagevimab/cilgavimab, nitazoxanide, favipiravir, remdesivir, ivermectin, ensitrelvir, ritonavir-337 boosted nirmatrelvir and molnupiravir) (Figure 1). Four patients from the fluoxetine group 338 withdrew consent. Two patients from the no study drug arm withdrew consent.

339

The majority of patients (89.6%) were enrolled in Bangkok, Thailand (Table 1). The median interval since symptom onset was 2 (IQR: 2 to 3) days. Most patients had high oropharyngeal eluate viral densities at presentation; average viral density of ~350,000 genomes per mL. Patients were infected with a wide variety of virus variants, the 3 most common being BA.2.75 (107/355), BA.5 (99/355) and XBB.1.5-like (63/355).

- 345
- 346



347



349 screening occurred in the Acute Respiratory Infection (ARI) unit of the Hospital for Tropical Diseases,

Bangkok. Potentially eligible patients were selected by the ARI Nurses to be contacted by the study team.

351 Therefore, a high proportion of those assessed for eligibility participated in the study.

	No study drug	Fluoxetine
All sites	150	116
Brazil	17 (11.3%)	12 (10.3%)
Thailand	129 (86.0%)	101 (87.1%)
Laos	0 (0%)	1 (0.9%)
Pakistan	4 (2.7%)	2 (1.7%)
Age (years) (SD)	30.5 (7.8)	29.5 (7.7)
Female N (%)	98 (65.3%)	82 (70.7)
Weight (kg) (SD)	62.7 (13.4)	59.6 (11.3)
Body mass index (kg/m ²) (SD)	23.2 (4.0)	22.3 (3.5)
Baseline oropharyngeal eluate viral	5.5 (1.4)	5.6 (1.3)
density		
(log ₁₀ copies per mL) (SD)		
Symptom onset (days) (SD)	2.1 (0.8)	2.2 (0.8)
Vaccinated (%)	150 (100.0%)	116 (100.0%)
SARS-CoV-2 variants		
BA.2 (%)	30 (20.0%)	24 (20.7%)
BA.2.3.20 (%)	0 (0.0%)	1 (0.9%)
BA.2.75 (%)	41 (27.3)	34 (29.3%)
BA.4 (%)	2(1.3%)	0 (0.0%)
BA.5 (%)	42 (28.0%)	31 (26.7%)
BN.1.9 (%)	2 (1.3)	0 (0.0%)
XBB (%)	10 (6.7%)	9 (7.8%)
XBB.1.5-like (%)	23 (15.3%)	15 (12.9%)
Others (%)	0 (0.0)	2 (1.7)

353

Table 1: Admission patient characteristics in the mITT population. For categorical variables, the number

354 (%) is shown and for continuous variables the standard deviation.

356 Tolerability

The oropharyngeal swabbing procedures and all treatments were well-tolerated. Patients allocated to the fluoxetine arm reported increased somnolence compared to the no study drug arm, and so the treatment was given in the evening.

360

361 Clinical responses

There were no serious adverse events (SAEs), hospitalisations or deaths in either arms, and no patients developed severe disease. There were no significant differences in times to symptom resolution or fever clearance between the fluoxetine and the no study drug arms, however this latter comparison had low power as only a quarter of patients were febrile at baseline (supplementary appendix figures S6 and S7).

367

368 Virological responses

369 Rates of viral clearance were estimated in the mITT population (6,362 measurements in 355 370 patients, of which 5,062 (80%) were above the lower limit of quantification). Under the linear 371 model fluoxetine resulted in a 15% (95% CrI: 2 to 34%) faster average rate of viral clearance over 372 7 days relative to no study drug. (Figure 2). The posterior probability that the effect of fluoxetine 373 was less than the pre-specified futility margin of 20% was 0.70. The non-linear model gave very 374 similar estimates: an acceleration in viral clearance rate of 11% (95% CrI -3 to 29%) relative to the 375 no study drug. Under the linear model, the median estimated viral clearance half-lives were 14.0 376 hours (9.3–18.0) with fluoxetine, and 14.9 hours (11.5–20.8) in the concurrent no study drug 377 group (Figure 3).

378

An in-depth analysis of all unblinded data (not including the fluoxetine arm) from the platform trial showed that viral clearance rates have increased substantially since the study began in September 2021.³⁰ This analysis indicated that maximal power to detect an antiviral effect was obtained from clearance rates estimated over the first 5 days (rather than 7 days). As a *post hoc* sensitivity analysis, we therefore estimated the treatment effect of fluoxetine using data only

- 384 from the first 5 days after randomisation. Under the linear and non-linear models, the estimated
- fluoxetine treatment effects were substantially larger: 26% (95% CrI: 5 to 50%) under the linear
- model; and 18% (95% CrI: 2 to 39%) under the non-linear model (Figure 2B).
- 387



388

Figure 2: Antiviral effect of fluoxetine in early COVID-19. Panel A: individual viral densities data (fluoxetine: dark green; no study drug: light green). Triangles show the daily median oropharyngeal eluate viral densities by arm. Panel B: posterior estimates of the treatment effects of fluoxetine relative to no study drug, under the linear and non-linear models (orange: viral clearance assessed over 7 days; green: viral clearance assessed over 5 days). Thick and thin error bars represent the 80% and 95% CrIs, respectively. The shaded area indicates the prespecified futility zone (<20% increase in viral clearance rate).



Viral clearance half-life

395

396

Figure 3: Estimated SARS-CoV-2 clearance half-lives (in hours) estimated over 7 days for individual patients
in the fluoxetine arm (dark green), and the no-study-drug arm (light green). The median estimates (circles)
and 80% credible intervals (error bars) are displayed. Vertical dashed lines indicate the median half-lives
of each group.

401

402 Meta-analysis

403 Under the linear model analysing viral clearance rates over 7 days, the meta-analysis including 404 all unblinded drugs (not concurrently randomised) and adjusting for calendar time and viral 405 variants, estimated that fluoxetine increased viral clearance by 16% (95% Crl 3 to 32%) compared 406 to the no study drug group (Figure 4). Fluoxetine treatment resulted in a higher viral clearance

rate than two interventions previously reported to have no clinical antiviral effect; 407 408 ivermectin²⁵ and favipiravir.²⁷ The treatment effect of fluoxetine was lower than that of casirivimab/imdevimab,²⁶ remdesivir,²⁶ molnupiravir,² and substantially lower than ritonavir-409 410 boosted nirmatrelvir,² with the probabilities of 0.88, 0.94, 0.98, and 1.00, respectively. These four 411 active antivirals/monoclonal antibodies increased the rates of viral clearance by 29% (95% Crl 10 to 48%), 35% (95% Crl 14 to 59%), 37% (95% Crl 18 to 60%), and 85% (95% Crl 61 to 112%), 412 413 respectively. Additionally, consistent with the main analysis, a post-hoc analysis of viral clearance 414 estimated over 5 days demonstrated higher discriminating power (figure 4B) indicated that 415 fluoxetine increased the viral clearance rate by 28% (95% Crl 11 to 49%).





417

418 Figure 4: Meta-analysis of oropharyngeal viral clearance rates in 783 patients in unblinded drug arms 419 (ritonavir-boosted nirmatrelvir, molnupiravir, remdesivir, casirivimab/imdevimab, fluoxetine, favipiravir, 420 and ivermectin relative to no study drug; not all concurrently) (A) Daily median oropharyngeal viral 421 loads by treatment group. (B) Posterior estimates of treatment effect on viral clearance rate relative to 422 no study drug under a model adjusting for calendar time and virus variant (orange: viral clearance 423 assessed over 7 days; green: viral clearance assessed over 5 days). Thick and thin error bars representing 424 the 80% and 95% Crls, respectively. The shaded area indicates the futility zone (<20% increase in viral 425 clearance rate).

426 Figure 4: Meta-analysis of oropharyngeal viral clearance rates in 783 patients in unblinded drug arms 427 (ritonavir-boosted nirmatrelvir, molnupiravir, remdesivir, casirivimab/imdevimab, fluoxetine, favipiravir, 428 and ivermectin relative to no study drug; not all concurrently) (A) Daily median oropharyngeal viral 429 loads by treatment group. (B) Posterior estimates of treatment effect on viral clearance rate relative to 430 no study drug under a model adjusting for calendar time and virus variant (orange: viral clearance 431 assessed over 7 days; green: viral clearance assessed over 5 days). Thick and thin error bars representing 432 the 80% and 95% Crls, respectively. The shaded area indicates the futility zone (<20% increase in viral 433 clearance rate).

434 Discussion

435 This clinical pharmacodynamic evaluation shows that the widely used SSRI fluoxetine, which has 436 the same proposed FIASMA mechanism of action as fluvoxamine, does have measurable, albeit 437 weak antiviral activity against SARS-CoV-2 in vivo. Earlier in the pandemic, before effective 438 antivirals and before vaccines were deployed, any available drug with anti-SARS-CoV-2 activity 439 could have played a role in the management of COVID-19. Based on several observational studies which reported lower mortalities in patients receiving SSRIs, ⁴⁻⁷ and some evidence for 440 prophylactic activity,⁸ the SSRIs fluoxetine and fluvoxamine were proposed as treatments for 441 442 early COVID-19. Both drugs are interesting choices as they are inexpensive, widely available, very 443 widely used, and have excellent safety profiles. A meta-analysis of randomised controlled trials 444 of fluvoxamine showed a slight, but non-significant reduction in hospitalisation +/- mortality 445 (Supplementary appendix; subsection S1). However, these results were not sufficient to change treatment policies and practices. In May 2022, the US FDA rejected an emergency use 446 authorisation (EUA) for fluvoxamine maleate in outpatients with COVID-19, on the basis that 447 448 there was insufficient evidence that fluvoxamine can prevent progression to severe disease or 449 hospitalisation. The US FDA noted that "it is unlikely that fluvoxamine possesses a high degree of 450 activity against SARS-CoV-2".³³ There have been no randomised controlled trials in outpatients 451 assessing fluoxetine.

452

In this comparative *in vivo* pharmacodynamic platform trial, carried out in low-risk adults with early symptomatic COVID-19 infection, fluoxetine demonstrated significant but weak antiviral activity. This was not sufficient for it to reach the prespecified success threshold of a 20%

456 acceleration of viral clearance (assessed over 7 days) compared to the contemporaneous control 457 group. This threshold was set because there are now highly effective antiviral drugs for early 458 symptomatic COVID-19, and so it is unlikely that drugs with a substantially lower potency would 459 be used in treatment. The main protease inhibitor nirmatrelvir, in combination with ritonavir, is 460 currently the most effective antiviral treatment assessed in this platform trial. In the 7-day 461 assessment its acceleration of viral clearance was over five times greater than that of fluoxetine. 462 But it has several disadvantages. Ritonavir-boosted nirmatrelvir is very expensive and often 463 unaffordable, it is not readily available worldwide, it produces an unpleasant taste, and ritonavir 464 is contraindicated in many patient groups due to drug interactions. So, although fluoxetine is 465 unlikely to be used in treatment now, it might still have a role in prevention where less antiviral activity is required than in the treatment of an already established infection (hence why lower 466 467 doses are effective in prophylaxis, than in treatment).

468

469 The methodology used in this platform trial is an effective way to measure antiviral effects in 470 COVID-19. Acceleration of viral clearance reflects the *in vivo* antiviral effect and correlates with prevention of hospitalisation and death.³⁴ It is becoming increasingly difficult to carry out large 471 472 trials with clinical endpoints. This is because the low rates of hospitalisation and death in COVID-473 19 infections with current viral variants in an increasingly immune population mean that sample sizes using these endpoints must be prohibitively large.²² Virological pharmacodynamic 474 endpoints can be used to measure antiviral effects with substantially smaller sample sizes. The 475 476 pharmacodynamic assessment has also become simpler. Increased rates of viral clearance since 477 the pandemic started now mean that viral clearance can be measured more accurately over 5 478 rather than 7 days.

479

The study has several limitations. It is open-label, which may have influenced the symptom reporting in each arm. There is substantial variability in estimated serial viral densities and much of the inter-subject variance in viral clearance rates is unexplained. There still remains some uncertainty about the antiviral potency of fluoxetine (at the doses evaluated). Whether larger

484 doses would have greater activity is not known, although tolerability would have been reduced.

485 The applicability of this result to other SSRIs or other FIASMAs was not determined.

486

487 In summary, fluoxetine demonstrates modest in vivo antiviral activity in early COVID-19. It 488 accelerated viral clearance by at least 15%, but this is much less than currently available effective 489 antivirals. Given that there are more effective, albeit much more expensive drugs, fluoxetine is 490 unlikely to be used in the treatment of COVID-19 at this stage of the pandemic, but whether it 491 could have had a useful role earlier is unclear. Fluoxetine might have a role either in prophylaxis, 492 or in high-risk patients unable to access or take other treatments, or in future pandemics, but 493 further evidence will be needed before such recommendations can be made. In vivo 494 pharmacodynamic assessments of drugs should be more widely adopted.

495 Acknowledgements

The trial was generously supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the
COVID-19 Therapeutics Accelerator.

498 We thank all the patients with COVID-19 who volunteered to be part of the study. We thank the 499 data safety and monitoring board (DSMB) (Tim Peto, André Sigueira, and Panisadee Avirutnan); 500 the trial steering committee (TSC) (Nathalie Strub-Wourgaft, Martin Llewelyn, Deborah Waller, 501 and Attavit Asavisanu); Sompob Saralamba and Tanaphum Wichaita for developing the RShiny 502 randomisation app; and Mavuto Mukaka for invaluable statistical support. We also thank all the 503 staff of the Clinical Trials Unit (CTU) at MORU, PCR Expert group (Janjira Thaipadungpanit, Audrey 504 Dubot-Pérès and Clare Ling), Thermo Fisher for their excellent support with this project, and all 505 the hospital staff at the Hospital for Tropical Diseases, Faculty of Tropical Medicine, as well as 506 those involved in sample processing in MORU and the processing and analysis at the Faculty of 507 Tropical Medicine (FTM), molecular genetics laboratory. We would thank the MORU Clinical Trials 508 Support Group (CTSG) for data management, monitoring, ethics and regulatory submissions and 509 logistics, and the purchasing, administration, and support staff at MORU, and those at the Brazil 510 site who provided expert help in managing patients (Joseane Fratari, Josiane Vaz and Fátima 511 Brant). We would finally like to thank everyone who supported the Laos and Pakistan sites.

512

513 Contributors

PJ- investigation, methodology, project administration, supervision, validation, and writing-514 515 original draft. SB- investigation, methodology, project administration, writing- original draft. PJ and SB contributed equally. WHKS- funding acquisition, investigation, methodology, project 516 517 administration, supervision, validation, and writing- original draft. JAW- conceptualisation, data 518 curation, formal analysis, funding acquisition, methodology, visualisation, and writing- original 519 draft. TN, TS, VL- Investigation, methodology, supervision. EMB- data curation, formal analysis, 520 visualisation. PW- data curation, formal analysis, visualisation, and writing- original draft. RA, FA, 521 NG- formal analysis, investigation. LE, PA, CC, JJC, SS, VK, TN, JT, FQ, AMK - methodology, 522 investigation, project administration. WM, KS, AP- investigation, methodology. BH, KP-

- 523 methodology, investigation, supervision. MP, AS, BL- resources. WRJT- methodology,
- 524 supervision. KC, MI- formal analysis, investigation, resources, supervision. SP, AMD, AB, MMT,
- 525 WP, WP, DC, SV methodology, investigation, resources, supervision. NPJD- funding acquisition,
- 526 methodology, investigation, resources, supervision. NJW- conceptualisation, funding acquisition,
- 527 methodology, supervision, validation, and writing- original draft.
- 528 All Authors were involved in writing- review & editing.
- 529 JAW, WHKS, EMB, TN, MI and NJW have directly accessed and verified the underlying data 530 reported in the manuscript.
- 531
- 532

533 **Declaration of interests**

- 534 We declare no competing interests
- 535

536 Data sharing statement

All code and de-identified participant data required for replication of the study's endpoints are openly accessible via GitHub, as well as the study protocol and statistical analysis plan, from publication date onwards: <u>https://github.com/jwatowatson/PLATCOV-Fluoxetine</u> Individual Patient Data can be requested and may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future from the date of publication. Further information on how to apply is found here: https://www.tropmedres.ac/units/morubangkok/bioethics-engagement/data-sharing.

544

546 **References**

547	1.	RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J
548		Med 2021; 384 : 693-704.
549	2.	Schilling WH, Jittamala P, Watson JA et al. Antiviral efficacy of molnupiravir versus ritonavir-
550		boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label,
551		phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis 2023; 24: 36-45
552	3.	Sanderson T, Hisner R, Donovan-Banfield IA et al. A molnupiravir-associated mutational
553		signature in global SARS-CoV-2 genomes. <i>Nature</i> . 2023; 623:594-600.
554	4.	Hoertel N, Sánchez-Rico M, Vernet R et al. Association between antidepressant use and reduced
555		risk of intubation or death in hospitalized patients with COVID-19: results from an observational
556		study. <i>Mol. Psychiatry</i> 2021; 26: 5199-5212
557	5.	Oskotsky T, Marić I, Tang A et al. Mortality Risk Among Patients With COVID-19 Prescribed
558		Selective Serotonin Reuptake Inhibitor Antidepressants. JAMA Netw Open 2021; 4:e2133090-e.
559	6.	Hoertel N, Sánchez-Rico M, Kornhuber J et al. Antidepressant use and its association with 28-day
560		mortality in inpatients with SARS-CoV-2: support for the FIASMA model against COVID-19. J Clin
561		Med 2022; 11 :5882.
562	7.	Hoertel N, Sánchez-Rico M, Gulbins E et al . Association between FIASMA psychotropic
563		medications and reduced risk of intubation or death in individuals with psychiatric disorders
564		hospitalized for severe COVID-19: an observational multicenter study. Transl Psychiatry 2022;
565		12 : 90.
566	8.	Clelland CL, Ramiah K, Steinberg L, Clelland JD. Analysis of the impact of antidepressants and
567		other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. B J Psych
568		<i>Open</i> 2022; 8 :e6.
569	9.	Lenze EJ, Mattar C, Zorumski CF et al. Fluvoxamine vs placebo and clinical deterioration in
570		outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020; 324: 2292-
571		2300.
572	10.	Reis G, dos Santos Moreira-Silva EA, Silva DC et al. Effect of early treatment with fluvoxamine on
573		risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER
574		randomised, platform clinical trial. Lancet Glob Hlth 2022; 1: 42-51

575	11.	Reis G, dos Santos Moreira Silva EA, Medeiros Silva DC et al. Oral Fluvoxamine with Inhaled
576		Budesonide for Treatment of Early-Onset COVID-19: A Randomized Platform Trial. Ann Intern
577		Med 2023; 176 :667-675.
578	12.	Reiersen AM, Mattar C, Bender Ignacio RA et al. The STOP COVID 2 Study: Fluvoxamine vs
579		Placebo for Outpatients with Symptomatic COVID-19, a Fully Remote Randomized Controlled
580		Trial. Open Forum Infect Dis 2023; 10 : ofad419
581	13.	Stewart TG, Rebolledo PA, Mourad A et al. Higher-Dose Fluvoxamine and Time to Sustained
582		Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA. 2023; 24:
583		2354-2363
584	14.	Bramante CT, Huling JD, Tignanelli CJ et al. Randomized trial of metformin, ivermectin, and
585		fluvoxamine for Covid-19. N Engl J Med 2022; 387 : 599-610.
586	15.	McCarthy MW, Naggie S, Boulware DR et al. Effect of fluvoxamine vs placebo on time to
587		sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial.
588		<i>JAMA</i> .2023; 329 : 296-305.
589	16.	Siripongboonsitti T, Ungtrakul T, Tawinprai K et al. Efficacy of combination therapy of
590		fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild
591		to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study). Int J
592		Infect Dis 2023; 134 : 211-219.
593	17.	Pauletto PJ, Delgado CP, da Rocha JB. Acid sphingomyelinase (ASM) and COVID-19: A review of
594		the potential use of ASM inhibitors against SARS-CoV-2. Cell Biochem. Funct 2023; 41:284-95.
595	18.	World Health Organization. WHO Model List of Essential Medicines - 23rd list, 2023
596	19.	Fred SM, Kuivanen S, Ugurlu H et al. Antidepressant and antipsychotic drugs reduce viral
597		infection by SARS-CoV-2 and fluoxetine shows antiviral activity against the novel variants in
598		vitro. <i>Front. Pharmacol.</i> 2022; 12 :75560 0
599	20.	Zimniak M, Kirschner L, Hilpert H et al. The serotonin reuptake inhibitor Fluoxetine inhibits
600		SARS-CoV-2 in human lung tissue. <i>Sci. Rep.</i> 2021; 1 :5890.
601	21.	Eugene AR. Fluoxetine pharmacokinetics and tissue distribution suggest a possible role in
602		reducing SARS-CoV-2 titers. F1000 Research. 2021; 10: 477.
603	22.	Butler CC, Hobbs FDR, Gbinigie OA et al. Molnupiravir plus usual care versus usual care alone as
604		early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC):
605		an open-label, platform-adaptive randomised controlled trial. Lancet. 2023; 401: 281-293.

606	23. Parienti JJ, o	le Grooth HJ. Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in
607	outpatients	with COVID-19. J Antimicrob Chemother. 2022; 77 : 2038-2039.
608	24. Elias KM, Kł	an SR, Stadler E et al. Viral clearance as a surrogate of clinical efficacy for COVID-19
609	therapies in	outpatients: A systematic review and meta-analysis. medRxiv. 2023;2023-06.
610	25. Schilling WH	l, Jittamala P, Watson JA et al. Pharmacometric assessment of the in vivo antiviral
611	activity of iv	ermectin in early symptomatic COVID-19. <i>eLife</i> 2023; 12 : e83201
612	26. Jittamala P,	Schilling WH, Watson JA et al. Clinical antiviral efficacy of remdesivir and
613	casirivimab,	imdevimab against the SARS-CoV-2 Delta and Omicron variants. medRxiv 2022; Oct
614	19, DOI:202	2.10.17.22281161.
615	27. Luvira V, Sc	nilling W, Jittamala P et al. Clinical antiviral efficacy of favipiravir in early COVID-19
616	(PLATCOV):	an open- label, randomised, controlled adaptive platform trial. Research Square;
617	2023 DOI:10).21203/rs.3.rs-2675703/v1
618	28. NIH Nationa	l Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version
619	5.0. Novem	per 27, 2017.
620	https://ctep	.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
621	eference_8	<u>5x11.pdf</u>
622	29. Watson JA,	Kissler SM, Day NPJ, Grad YH, White NJ. Characterizing SARS-CoV-2 Viral Clearance
623	Kinetics to I	mprove the Design of Antiviral Pharmacometric Studies. Antimicrob Agents
624	Chemother.	2022; 66 : e0019222.
625	30. Wongnak P	, Schilling WH, Jittamala P et al. Temporal changes in SARS-CoV-2 clearance kinetics
626	and the opt	mal design of phase 2 antiviral studies. MedRxiv [Preprint] 2024
627	31. Stan Develo	pment Team (2023). "RStan: the R interface to Stan." R package version 2.32.3,
628	https://mc-	stan.org/.
629	32. Vehtari A, G	elman A, Gabry J. "Practical Bayesian model evaluation using leave-one-out cross-
630	validation a	nd WAIC." Stat Comput 2017; 27: 1413-1432.
631	33. Memorand	am explaining basis for declining request for emergency use authorization of
632	fluvoxamine	maleate. News release. US Food and Drug Administration. Accessed Dec 15, 2023.
633	https://www	w.accessdata.fda.gov/drugsatfda_docs/nda/2020/EUA%20110%20Fluvoxamine%20
634	Decisional%	20Memo_Redacted.pdf
635	34. Hammond J	, Leister-Tebbe H, Gardner A et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized
636	Adults with	Covid-19. <i>N Engl J Med.</i> 2022; 15 :1397-1408.